Verger Antoine, Tolboom Nelleke, Cicone Francesco, Chang Susan M, Furtner Julia, Galldiks Norbert, Gempt Jens, Guedj Eric, Huang Raymond Y, Johnson Derek R, Law Ian, Le Rhun Emilie, Short Susan C, Bent M J Van den, Weehaeghe Donatienne Van, Vogelbaum Michael A, Wen Patrick Y, Albert Nathalie L, Preusser Matthias
Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM, UMR 1254, Université de Lorraine, Nancy, France.
Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1822-1839. doi: 10.1007/s00259-024-07038-5. Epub 2025 Jan 7.
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.
本联合实践指南/程序标准由欧洲核医学协会(EANM)、核医学与分子影像学会(SNMMI)、欧洲神经肿瘤协会(EANO)以及神经肿瘤学反应评估工作组的PET特别工作组(PET/RANO)共同制定。脑转移瘤是最常见的恶性中枢神经系统(CNS)肿瘤。使用放射性标记氨基酸的PET成像以及在较小程度上使用[F]FDG的PET成像在脑转移瘤的评估中已变得相当重要,特别是对于复发性转移瘤与治疗相关改变之间的鉴别诊断,而这在使用传统MRI时仍然是一个局限。本指南的目的是协助核医学医师推荐、进行、解读和报告脑转移瘤患者脑PET成像的结果。本实践指南将定义在常规实践和临床试验中对脑转移瘤患者应用PET成像的程序标准,并将有助于协调各中心的数据采集和解读。